The antipsychotic drug Risperdal is causing a whirlwind of lawsuits in courtrooms around the country as victims of this drug, mostly male, are getting what they haven't signed up for. Men and boys who take the antipsychotic drug to treat bipolar disorder and schizophrenia are developing gynecomastia, male breast growth. More recently, however, Risperdal is being used to treat patients with Attention Deficit Hyperactivity Disorder, off-label use of which hasn't been approved by the FDA. Although Johnson & Johnson, the maker of the drug, had settled countless claims, much more arise to take their place.
Many Risperdal cases involve children, especially young boys who have developed male breasts as a result of the drug's use.
As of February 2015, nearly 1,300 cases involving Risperdal have been reported in Pennsylvania alone. Johnson & Johnson and its pharmaceutical arm have been accused of promoting the off-label use and, as a result, they agreed to pay $2.2 billion to resolve similar charges involving Risperdal and a number of other drugs in a settlement with the U.S. Department of Justice.